60
Participants
Start Date
January 15, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
September 30, 2027
NTLA-2002
CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
Normal Saline IV Administration
The administration of intravenous (IV) normal saline
New Zealand Clinical Research (NZCR), Auckland
Campbelltown Hospital, Campbelltown
The Alfred Hospital, Melbourne
Royal Melbourne Hospital, Parkville
University of Cape Town - Lung Institute - Lung Clinical Research Unit, Cape Town
Icahn School of Medicine at Mount Sinai, New York
NYU Langone Health - Long Island, Mineola
Charite Universitaetsmedizin Berlin, Berlin
AP-HM - Hopital de la Timone, Marseille
Penn State Milton S. Hershey Medical Center, Hershey
Medizinische Hochschule Hannover (MHH), Hanover
University of South Florida, Tampa
CHU Grenoble-Alpes - Hopital Michallon, Grenoble
Optimed Research, LTD, Columbus
Bernstein Clinical Research Center, LLC, Cincinnati
Henry Ford Health System, Detriot
CHU de Lille - Hopital Claude Huriez, Lille
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt
Washington University in St. Louis, St Louis
AARA Research Center, Dallas
IMMUNOe International Research Centers, Centennial
Asthma & Allergy Associates, Colorado Springs
Medical Research of Arizona, Scottsdale
Raffi Tachdjian MD, Inc, Santa Monica
University of California, San Diego (UCSD), San Diego
Allergy & Asthma Clinical Research, Walnut Creek
Massachusetts General Hospital, Boston
University of Alberta, Edmonton
Ottawa Allergy Research Corporation, Ottawa
Amsterdam UMC - Locatie AMC, Amsterdam
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Lead Sponsor
Intellia Therapeutics
INDUSTRY